<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877185</url>
  </required_header>
  <id_info>
    <org_study_id>3-Injection-Protocol-AN008</org_study_id>
    <nct_id>NCT03877185</nct_id>
  </id_info>
  <brief_title>A New Revolutionary 3-Injection- Protocol in Infertile Women</brief_title>
  <official_title>A New Revolutionary 3-Injection- Protocol in Infertile Women With a Single Long Acting GnRH Antagonist in the Luteal Phase, a Bolus Gonadotropin Injection in the Early Follicular Phase and a Single Triggering Dose.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assisting Nature</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assisting Nature</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomised study of the evaluation of the clinical IVF results after
      following a new revolutionary 3-Injection- Protocol for controlled ovarian stimulation in
      infertile women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized prospective study focusing on infertile women undergoing ovarian stimulation for
      IVF, using Elonva (corifollitropin alfa) as part of two different stimulation protocols.

      Women assigned to Protocol A receive a bolus late luteal dose of Degarelix, a new long acting
      GnRH antagonist, a sole Elonva injection in the evening of day 3 of the cycle, followed by
      the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to
      the individual response).

      Women assigned to Protocol B are administered a single dose of Elonva (corifollitropin alfa)
      on day 2 of the cycle, followed by daily GnRH antagonist doses, fixed on day 7 of the cycle.
      Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a,
      accordingly.

      Live Birth Rates are estimated for both groups of patients. The number of the formed
      blastocysts in each group is measured, as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate according to stimulation protocol</measure>
    <time_frame>Up to 38 weeks after embryo transfer</time_frame>
    <description>Live birth rate according to stimulation protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blastulation rate according to stimulation protocol</measure>
    <time_frame>Up to 6 days post oocyte retrieval</time_frame>
    <description>Blastulation rate according to stimulation protocol</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>3-Injection-Protocol Group</arm_group_label>
    <description>Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple-Injection- Protocol Group</arm_group_label>
    <description>Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Live birth rate</intervention_name>
    <description>Live Birth Rate and Blastulation Rate according to the protocol of COS</description>
    <arm_group_label>3-Injection-Protocol Group</arm_group_label>
    <arm_group_label>Multiple-Injection- Protocol Group</arm_group_label>
    <other_name>Blastulation rate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women aged 22- 39, faced with infertility issues, meeting the above inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary infertility

          -  age 22-39 years;

          -  body mass index (BMI) 18-29kg/m2;

          -  regular menstrual cycle of 26-35 days,

          -  presumed to be ovulatory;

          -  early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

        Exclusion Criteria:

          -  women with diabetes and other metabolic disease

          -  women with heart disease, QT prolongation, heart failure

          -  elevated liver enzymes, liver failure, hepatitis

          -  women with inflammatory or autoimmune disease

          -  abnormal karyotype

          -  polycystic ovarian syndrome

          -  endometriosis stage III/IV
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evaggelos Papanikolaou, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisting Nature</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Najdecki, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisting Nature</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evaggelos Papanikolaou, MD,PhD</last_name>
    <phone>00302310424294</phone>
    <email>drvagpapanikolaou@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assisting Nature</name>
      <address>
        <city>Thessalon√≠ki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evaggelos Papanikolaou, MD, PhD</last_name>
      <phone>00302310424294</phone>
      <email>papanikolaou@assistingnature.gr</email>
    </contact>
    <contact_backup>
      <last_name>Robert Najdecki, MD, PhD</last_name>
      <phone>00306936646464</phone>
      <email>rnajdecki@assistingnature.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assisting Nature</investigator_affiliation>
    <investigator_full_name>Papanikolaou Evaggelos</investigator_full_name>
    <investigator_title>Papanikolaou Evaggelos, MD, PhD, Fertility Specialist, Scientific Director at Assisting Nature IVF Clinic</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>infertility</keyword>
  <keyword>long antagonist</keyword>
  <keyword>long acting gonadotropin</keyword>
  <keyword>corifollitropin alfa</keyword>
  <keyword>ovarian stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

